Bioforce Nanosciences Holdings Stock Performance
| BFNH Stock | USD 1.09 0.00 0.00% |
The firm shows a Beta (market volatility) of 1.91, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioForce Nanosciences will likely underperform. At this point, BioForce Nanosciences has a negative expected return of -0.0147%. Please make sure to confirm BioForce Nanosciences' variance, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if BioForce Nanosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BioForce Nanosciences Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, BioForce Nanosciences is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 39.9 K |
BioForce |
BioForce Nanosciences Relative Risk vs. Return Landscape
If you would invest 133.00 in BioForce Nanosciences Holdings on September 2, 2024 and sell it today you would lose (24.00) from holding BioForce Nanosciences Holdings or give up 18.05% of portfolio value over 90 days. BioForce Nanosciences Holdings is currently does not generate positive expected returns and assumes 7.9631% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of pink sheets are less volatile than BioForce, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioForce Nanosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioForce Nanosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as BioForce Nanosciences Holdings, and traders can use it to determine the average amount a BioForce Nanosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0018
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BFNH |
Estimated Market Risk
| 7.96 actual daily | 70 70% of assets are less volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioForce Nanosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioForce Nanosciences by adding BioForce Nanosciences to a well-diversified portfolio.
BioForce Nanosciences Fundamentals Growth
BioForce Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BioForce Nanosciences, and BioForce Nanosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioForce Pink Sheet performance.
| Return On Asset | -21.84 | |||
| Current Valuation | 50.2 M | |||
| Shares Outstanding | 29.27 M | |||
| Price To Earning | (1.52) X | |||
| Price To Book | 866.24 X | |||
| Price To Sales | 3,841 X | |||
| EBITDA | (501.95 K) | |||
| Cash And Equivalents | 9.23 K | |||
| Total Debt | 156.87 K | |||
| Debt To Equity | 4.61 % | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (77.77 K) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 11.14 K | |||
| Retained Earnings | (21 K) | |||
| Current Asset | 15 K | |||
| Current Liabilities | 1 K | |||
About BioForce Nanosciences Performance
By evaluating BioForce Nanosciences' fundamental ratios, stakeholders can gain valuable insights into BioForce Nanosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioForce Nanosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioForce Nanosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, and mass merchandisers under the BioForce Eclipse brand, as well as through online and telemarketing. BIOFORCE NANOSCIENCES operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about BioForce Nanosciences performance evaluation
Checking the ongoing alerts about BioForce Nanosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BioForce Nanosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioForce Nanosciences generated a negative expected return over the last 90 days | |
| BioForce Nanosciences has high historical volatility and very poor performance | |
| BioForce Nanosciences has some characteristics of a very speculative penny stock | |
| BioForce Nanosciences Holdings currently holds 156.87 K in liabilities with Debt to Equity (D/E) ratio of 4.61, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioForce Nanosciences has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioForce Nanosciences until it has trouble settling it off, either with new capital or with free cash flow. So, BioForce Nanosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioForce Nanosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioForce to invest in growth at high rates of return. When we think about BioForce Nanosciences' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (501.95 K) with profit before overhead, payroll, taxes, and interest of 4.36 K. | |
| BioForce Nanosciences Holdings currently holds about 9.23 K in cash with (77.77 K) of positive cash flow from operations. | |
| Roughly 82.0% of BioForce Nanosciences shares are held by company insiders |
- Analyzing BioForce Nanosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioForce Nanosciences' stock is overvalued or undervalued compared to its peers.
- Examining BioForce Nanosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioForce Nanosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioForce Nanosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioForce Nanosciences' pink sheet. These opinions can provide insight into BioForce Nanosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioForce Pink Sheet analysis
When running BioForce Nanosciences' price analysis, check to measure BioForce Nanosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioForce Nanosciences is operating at the current time. Most of BioForce Nanosciences' value examination focuses on studying past and present price action to predict the probability of BioForce Nanosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioForce Nanosciences' price. Additionally, you may evaluate how the addition of BioForce Nanosciences to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |